-
公开(公告)号：KR1020200129456A
公开(公告)日：2020-11-18
申请号：KR1020190053883
申请日：2019-05-08
Applicant: 서울대학교산학협력단 , 순천대학교 산학협력단
IPC: C07D493/04 , A61K31/352 , A61K31/365 , A61K36/062 , C07D493/14 , A61P19/10 , A23K20/121 , A23K20/126
Abstract: 본발명은메로터페노이드계화합물, 그의수화물, 그의용매화물, 그의입체이성체, 생체내에서가수분해가능한그의전구체또는그의약학적으로허용가능함염 및이를포함하는골다공증예방또는치료용약제학적조성물에관한것이다.
-
公开(公告)号：KR20180048534A
公开(公告)日：2018-05-10
申请号：KR20180049984
申请日：2018-04-30
Applicant: 서울대학교산학협력단
IPC: A61K31/426 , A61K31/427
CPC classification number: A61K31/426 , A61K31/427 , Y10S514/866 , Y10S514/909
Abstract: 본발명은피피에이알델타(PPARδ) 활성물질(agonist)의새로운용도에관한것으로, 구체적으로는 PPARδ활성물질의태자재프로그래밍(fetal reprogramming) 효능에대한것이다. 본발명에따르면, PPARδ활성물질은태자발생및 초기발육시기에칼슘이온을조절하여지근섬유를증가시켜근 지구력을향상시킴으로써지질및 당대사능력을향상시키고몸 전체의대사를재프로그래밍(metabolic reprogramming)하여성인또는성체에서고지방식이및 운동부족에의한비만당뇨등의대사성질환의발병을예방/억제하고, 기억력을증가시킨다. 또한 PPARδ활성물질을이용한태자재프로그래밍은당뇨질환모델마우스에서도당뇨의발병을예방/억제시킨다. 따라서 PPARδ활성물질은태아/태자재프로그래밍에의한인간및 동물의지구력증진, 비만·당뇨·동맥경화·지방간등의대사성질환예방/억제, 기억력증진을목적으로하는의약조성물, 임산부용보조제, 식품첨가제, 기능성식품보조제또는기능성음료조성물, 동물용의약조성물, 동물용지구력증진제, 분유및 이유식조성물, 동물사료조성물등으로사용할수 있다.
-
公开(公告)号：KR1020140024221A
公开(公告)日：2014-02-28
申请号：KR1020130096070
申请日：2013-08-13
Applicant: 서울대학교산학협력단
Inventor： 강헌중 , 왕웨이홍 , 김희영 , 기리아왓두트가젠드라
IPC: C07D307/58 , A61K31/341 , A61P31/04 , A61P37/00
CPC classification number: C07D307/58
Abstract: The present invention relates to a butenolides compound, the stereoisomers and enantiomers thereof, precursors thereof which is hydrolyzable in the body, or a pharmaceutically acceptable salt, the antimicrobial activity, preventive activity against immune diseases, effects in preventing or treating cancer, and preventive activity against fouling of a medical introducer.
Abstract translation: 本发明涉及丁内酯化合物，其立体异构体和对映异构体，其在体内可水解的前体或其药学上可接受的盐，抗微生物活性，针对免疫疾病的预防活性，预防或治疗癌症的预防作用和预防活性 防止医疗导师的结垢。
-
公开(公告)号：KR101012313B1
公开(公告)日：2011-02-09
申请号：KR1020080054293
申请日：2008-06-10
Applicant: 서울대학교산학협력단
IPC: A61K31/201 , A61K31/075 , A61P29/00
Abstract: 본 발명은 하기 화학식 1로 표시되는 화합물을 유효성분으로 함유하는 염증질환 치료제에 관한 것으로, 이러한 화합물은 LPS로 활성화된 RAW 264.7세포에서 NO, IL-6 및 TNF-a와 같은 염증성 매개물의 생성을 억제함으로써 염증 질환의 치료제로서 유용하게 이용될 수 있다.
[화학식 1]
염증질환, NO, IL-6, TNF-α-
公开(公告)号：KR1020100043703A
公开(公告)日：2010-04-29
申请号：KR1020080102855
申请日：2008-10-21
Applicant: 서울대학교산학협력단
IPC: C07C391/02
Abstract: PURPOSE: A method for a potassium organoselanyltrifluoroborate derivative is provided to prepare various potassium organoselanyltrifluoroborate derivatives containing selenium in a short reaction time without a process of refining an intermediate from a dihalogen aryl compound. CONSTITUTION: A method for a potassium organoselanyltrifluoroborate derivative comprises the steps of: preparing an organic selenium compound by mixing a dihalogen aryl compound, selenium powder and organic halogen compound, and then selectively reacting with an alkyl lithium reagent; and reacting the organic selenium compound with a trialkyl borate compound and the alkyl lithium reagent; and reacting with potassium hydrogen fluoride(KHF2).
Abstract translation: 目的：提供一种钾有机硅烷基三氟硼酸盐衍生物的方法，以在短的反应时间内制备各种含有硒的有机硅烷基三氟硼酸盐衍生物，而不需要从二卤代芳基化合物中精制中间体。 组成：有机硅烷基三氟硼酸钾衍生物的方法包括以下步骤：通过混合二卤代芳基化合物，硒粉和有机卤素化合物，然后选择性地与烷基锂试剂反应来制备有机硒化合物; 并使有机硒化合物与硼酸三烷基酯化合物和烷基锂试剂反应; 并与氟化氢钾（KHF 2）反应。
-
Patent Agency Ranking
公开(公告)号：KR1020090128229A
公开(公告)日：2009-12-15
申请号：KR1020080054293
申请日：2008-06-10
Applicant: 서울대학교산학협력단
IPC: A61K31/201 , A61K31/075 , A61P29/00
Abstract: PURPOSE: A therapeutic agent containing a compound as an active ingredient for treating inflammatory disease is provided to suppress generation of inflammatory media such as NO(nitrogen oxide), IL-6(interleukin-6) and TNF-α(tumor necrosis factor-alpha) in LPS-activated RAW 264.7 cell. CONSTITUTION: A therapeutic agent for treating inflammatory diseases contains a compound of the chemical formula 1 as an active ingredient. In chemical formula 1, R is COOH, COOCH3, CH2OH or CH2NHCOCF3, R1 and R2 is H, C6H5, or Br, and m is 1-5 integer and n is 1-4 integer. The compound of chemical formula 1 is (E)-11-oxooctadeca-9-enole, (E)-10- oxooctadeca-8-enole, (E)-9-oxooctadeca-10-enole or (E)-8-oxooctadeca-9-enole. The inflammatory diseases are rheumatoid arthritis, inflammatory bowel disease, osteoporosis, psoriasis, or toxic shock syndrome.
Abstract translation: 目的：提供含有化合物作为治疗炎性疾病的活性成分的治疗剂，以抑制炎症介质如NO（氮氧化物），IL-6（白细胞介素-6）和TNF-α（肿瘤坏死因子-α ）在LPS激活的RAW 264.7细胞中。 构成：用于治疗炎性疾病的治疗剂含有化学式1的化合物作为活性成分。 在化学式1中，R为COOH，COOCH3，CH2OH或CH2NHCOCF3，R1和R2为H，C6H5或Br，m为1-5整数，n为1-4整数。 化学式1的化合物是（E）-11-氧代十八碳-9-烯醇，（E）-10-氧代十八碳-8-烯醇，（E）-9-氧代十八碳-10-烯醇或（E）-8-氧代十八碳烯 -9- enole。 炎症性疾病是类风湿性关节炎，炎性肠病，骨质疏松症，牛皮癣或中毒性休克综合征。
-
公开(公告)号：KR102038866B1
公开(公告)日：2019-10-31
申请号：KR1020120152442
申请日：2012-12-24
Applicant: 서울대학교산학협력단
IPC: A61K31/426 , A61K31/427 , A61K31/41 , A61K31/192 , A61K31/4439
-
公开(公告)号：KR1020130069463A
公开(公告)日：2013-06-26
申请号：KR1020120145699
申请日：2012-12-13
Applicant: 세종대학교산학협력단 , 서울대학교산학협력단
IPC: C07D493/22 , A61K31/335 , A61P35/00
Abstract: PURPOSE: A pectenotoxin-2 derivative with various useful physical properties is provided to be used as an anticancer agent or a precursor thereof. CONSTITUTION: A pectenotoxin-2 derivative is denoted by chemical formula 1. An anticancer composition contains the derivative and removes cancer cells in human body. The cancer cells include cancer cells of lung, colon, central nervous system, skin, ovary, kidney, breast, or stomach.
Abstract translation: 目的：提供具有各种有用物理性质的果胶毒素-2衍生物作为抗癌剂或其前体。 构成：化学式1表示果胶毒素-2衍生物。抗癌组合物含有衍生物并去除人体中的癌细胞。 癌细胞包括肺，结肠，中枢神经系统，皮肤，卵巢，肾，乳腺或胃的癌细胞。
-
公开(公告)号：KR1020130051523A
公开(公告)日：2013-05-21
申请号：KR1020110116487
申请日：2011-11-09
Applicant: 서울대학교산학협력단
IPC: A61K31/352 , A23K1/17 , A23K1/18 , A61K35/74
CPC classification number: Y02A50/469 , Y02A50/471 , A61K31/352 , A61K35/74
Abstract: PURPOSE: A use of a Paecilomyces variotii extract for preventing or treating pathogenic bacterial infection in fish is provided to ensure immunity to fish diseases, and to prevent bacterial infection in fish. CONSTITUTION: A composition for preventing or treating pathogenic bacterial infection in fish contains an organic solvent extract of Paecilomyces variotii as an active ingredient. The organic solvent is selected from the group consisting of n-hexane, chloroform, ethyl acetate, and butanol. The organic solvent is ethyl acetate. The composition contains a compound denoted by chemical formula 1 as an active ingredient. A method for preventing or treating pathogenic bacterial infection in fish comprises a step of directly treating a water bath in which fish grows with the composition, or adsorbing the composition to a feed for growing fish in a concentration of 1.0-500ppm.
Abstract translation: 目的：提供拟青霉提取物用于预防或治疗鱼类病原菌感染的用途，以确保对鱼类疾病的免疫力，并防止鱼类细菌感染。 构成：用于预防或治疗鱼类病原菌感染的组合物含有拟青霉的有机溶剂提取物作为活性成分。 有机溶剂选自正己烷，氯仿，乙酸乙酯和丁醇。 有机溶剂为乙酸乙酯。 组合物含有化学式1表示的化合物作为有效成分。 用于预防或治疗鱼类病原菌感染的方法包括直接处理其中鱼类与组合物生长的水浴或将组合物吸附至浓度为1.0-500ppm的鱼饲料的步骤。
-
公开(公告)号：KR1020120025440A
公开(公告)日：2012-03-15
申请号：KR1020110090896
申请日：2011-09-07
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , A61K31/352 , A61P3/10 , A61P9/00
CPC classification number: C07D493/10 , A61K31/352 , A61K31/4184 , A61K31/4192 , A61K31/422 , A61K31/453 , A61K31/496 , A61K31/541 , A61K31/665 , A61K31/7048 , A61K45/06 , C07D493/20 , C07F9/65615 , C07H17/04
Abstract: PURPOSE: A sesterterpen compound and a composition containing the same are provided to prevent and treat diabetes, fatty liver, and obesity. CONSTITUTION: A sesterterpen compound is denoted by chemical formula I. A pharmaceutical composition for preventing and treating diabetes, diabetes complication, cardiovascular diseases or obesity contains sesterterpen compounds, stereoisomer, enantiomer, hybridizable precursor, or pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing and treating cardiovascular diseases contains sesterterpen compounds of chemical formula I, stereoisomer, enantiomer, in vivo hybridizable precursor thereof, or pharmaceutically acceptable salt thereof, and LXR agonist.
Abstract translation: 目的：提供西酯化合物和含有它们的组合物以预防和治疗糖尿病，脂肪肝和肥胖。 构成：化学式I表示酯化合物。用于预防和治疗糖尿病，糖尿病并发症，心血管疾病或肥胖症的药物组合物含有酯化合物，立体异构体，对映异构体，可杂交前体或其药学上可接受的盐。 用于预防和治疗心血管疾病的药物组合物含有化学式I的酯化合物，立体异构体，对映异构体，体内可杂交的前体或其药学上可接受的盐和LXR激动剂。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.03 seconds)
